Premium
Poly(ADP‐ribose) polymerase‐1, a novel partner of progesterone receptors in endometrial cancer and its precursors
Author(s) -
Ghabreau Lina,
Roux Jean Paul,
Frappart PierreOlivier,
Mathevet Patrice,
Patricot Louis Marc,
Mokni Moncef,
Korbi Sadok,
Wang ZhaoQi,
Tong WeiMin,
Frappart Lucien
Publication year - 2004
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.11731
Subject(s) - endometrial cancer , poly adp ribose polymerase , carcinogenesis , progesterone receptor , cancer research , downregulation and upregulation , medicine , receptor , endocrinology , biology , malignancy , cancer , polymerase , chemistry , estrogen receptor , dna , gene , genetics , breast cancer
Endometrial carcinomas are the most common malignancy of the female genital tract. Although the downregulation of the progesterone receptor (PR) in the progression of endometrioid carcinomas (ECs) has been well documented, the mechanism of PR alteration in endometrioid carcinogenesis is poorly understood. Recently, biochemical studies have shown that the DNA strand break‐sensing molecule poly(ADP‐ribose) polymerase (PARP‐1) was associated with the DNA binding domain of PR. In our present study, we show that in normal endometrial epithelium, the expression level of PARP‐1 protein is high in the proliferative phase but markedly decreases during the secretory phase. Interestingly, PARP‐1 expression gradually increases in nonatypical and atypical endometrial hyperplasia, reaching its highest level in grade I, and decreases significantly toward grade III ECs. Notably, PARP‐1 and PR expressions, in each stage, are positively correlated ( p < 0.0001), with the exception of nonendometrioid carcinomas. Thus, these data suggest that PARP‐1 is substantially involved in the regulation of progesterone action in the development of ECs. © 2004 Wiley‐Liss, Inc.